These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25462281)

  • 1. Structural development studies of PPARs ligands based on tyrosine scaffold.
    De Filippis B; Linciano P; Ammazzalorso A; Di Giovanni C; Fantacuzzi M; Giampietro L; Laghezza A; Maccallini C; Tortorella P; Lavecchia A; Loiodice F; Amoroso R
    Eur J Med Chem; 2015 Jan; 89():817-25. PubMed ID: 25462281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
    Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, in vitro and in silico evaluation of l-tyrosine containing PPARalpha/gamma dual agonists.
    Kumar R; Ramachandran U; Khanna S; Bharatam PV; Raichur S; Chakrabarti R
    Bioorg Med Chem; 2007 Feb; 15(3):1547-55. PubMed ID: 17166722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.
    Collins JL; Blanchard SG; Boswell GE; Charifson PS; Cobb JE; Henke BR; Hull-Ryde EA; Kazmierski WM; Lake DH; Leesnitzer LM; Lehmann J; Lenhard JM; Orband-Miller LA; Gray-Nunez Y; Parks DJ; Plunkett KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5037-54. PubMed ID: 9836621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα.
    Lamers C; Dittrich M; Steri R; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem Lett; 2014 Aug; 24(16):4048-52. PubMed ID: 25022880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
    Cobb JE; Blanchard SG; Boswell EG; Brown KK; Charifson PS; Cooper JP; Collins JL; Dezube M; Henke BR; Hull-Ryde EA; Lake DH; Lenhard JM; Oliver W; Oplinger J; Pentti M; Parks DJ; Plunket KD; Tong WQ
    J Med Chem; 1998 Dec; 41(25):5055-69. PubMed ID: 9836622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Design, synthesis and PPAR agonist activities of novel L-tyrosine derivatives containing phenoxyacetyl moiety].
    Zhou LJ; Yan JF; Zhang K; Fan L; Chen X; Yang DC
    Yao Xue Xue Bao; 2013 Oct; 48(10):1570-8. PubMed ID: 24417084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation.
    Fresno N; Macías-González M; Torres-Zaguirre A; Romero-Cuevas M; Sanz-Camacho P; Elguero J; Pavón FJ; Rodríguez de Fonseca F; Goya P; Pérez-Fernández R
    J Med Chem; 2015 Aug; 58(16):6639-52. PubMed ID: 26226490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
    Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
    Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.
    Rikimaru K; Wakabayashi T; Abe H; Tawaraishi T; Imoto H; Yonemori J; Hirose H; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
    Bioorg Med Chem; 2012 May; 20(10):3332-58. PubMed ID: 22503460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Study on Selective PPAR Modulators through Quantitative Structure-activity Relationship, Pharmacophore and Docking Analyses.
    Nandy A; Roy K; Saha A
    Curr Comput Aided Drug Des; 2018; 14(1):54-67. PubMed ID: 28595521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
    Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors.
    Miyachi H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation.
    Wei ZL; Petukhov PA; Bizik F; Teixeira JC; Mercola M; Volpe EA; Glazer RI; Willson TM; Kozikowski AP
    J Am Chem Soc; 2004 Dec; 126(51):16714-5. PubMed ID: 15612696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands.
    Laghezza A; Piemontese L; Tortorella P; Loiodice F
    Eur J Med Chem; 2019 Aug; 176():326-342. PubMed ID: 31112893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships of dimeric PPAR agonists.
    Sauerberg P; Mogensen JP; Jeppesen L; Svensson LA; Fleckner J; Nehlin J; Wulff EM; Pettersson I
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1497-500. PubMed ID: 15713415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.